CA2715373C - Modele humanise de la formation du complexe d'attaque membranaire (mac) sur la retine murine et compositions, trousses et procedes de traitement de la degenerescence maculaire - Google Patents

Modele humanise de la formation du complexe d'attaque membranaire (mac) sur la retine murine et compositions, trousses et procedes de traitement de la degenerescence maculaire Download PDF

Info

Publication number
CA2715373C
CA2715373C CA2715373A CA2715373A CA2715373C CA 2715373 C CA2715373 C CA 2715373C CA 2715373 A CA2715373 A CA 2715373A CA 2715373 A CA2715373 A CA 2715373A CA 2715373 C CA2715373 C CA 2715373C
Authority
CA
Canada
Prior art keywords
cells
protein
mac
soluble
panel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2715373A
Other languages
English (en)
Other versions
CA2715373A1 (fr
Inventor
Rajendra Kumar-Singh
Siobhan M. Cashman
Kasmir Ramo
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CA2715373A1 publication Critical patent/CA2715373A1/fr
Application granted granted Critical
Publication of CA2715373C publication Critical patent/CA2715373C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour le traitement dun patient atteint de dégénérescence maculaire liée à lâge (DMA), des procédés de dosage de la dégénérescence maculaire (DM) humaine, et des procédés et des trousses permettant de doser des agents thérapeutiques potentiels pour le traitement de la DM humaine.
CA2715373A 2008-02-15 2009-02-13 Modele humanise de la formation du complexe d'attaque membranaire (mac) sur la retine murine et compositions, trousses et procedes de traitement de la degenerescence maculaire Active CA2715373C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6606208P 2008-02-15 2008-02-15
US61/066,062 2008-02-15
US6628808P 2008-02-19 2008-02-19
US61/066,288 2008-02-19
US7065008P 2008-03-25 2008-03-25
US61/070,650 2008-03-25
PCT/US2009/000947 WO2009102488A2 (fr) 2008-02-15 2009-02-13 Modèle humanisé de la formation du complexe d’attaque membranaire (mac) sur la rétine murine et compositions, trousses et procédés de traitement de la dégénérescence maculaire

Publications (2)

Publication Number Publication Date
CA2715373A1 CA2715373A1 (fr) 2009-08-20
CA2715373C true CA2715373C (fr) 2019-11-05

Family

ID=40957438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2715373A Active CA2715373C (fr) 2008-02-15 2009-02-13 Modele humanise de la formation du complexe d'attaque membranaire (mac) sur la retine murine et compositions, trousses et procedes de traitement de la degenerescence maculaire

Country Status (9)

Country Link
US (1) US8324182B2 (fr)
EP (1) EP2252317B1 (fr)
JP (2) JP5697027B2 (fr)
AU (1) AU2009215118B2 (fr)
CA (1) CA2715373C (fr)
DK (1) DK2252317T3 (fr)
ES (1) ES2478820T3 (fr)
PL (1) PL2252317T3 (fr)
WO (1) WO2009102488A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
WO2012016162A2 (fr) * 2010-07-29 2012-02-02 Tufts University Compositions, procédés et kits pour modéliser, diagnostiquer et traiter des troubles du complément
WO2011066471A1 (fr) 2009-11-25 2011-06-03 Loma Linda University Medical Center Textile hemostatique a base de chitosane
CA2843684A1 (fr) 2010-08-13 2012-02-16 Tufts University Compositions, trousses et methodes de traitement de la degenerescence maculaire au moyen de la proteine cd59 soluble independante de la membrane
WO2012075023A2 (fr) 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Néoanticorps pour le diagnostic d'une lésion tissulaire
WO2013138368A1 (fr) * 2012-03-12 2013-09-19 Loma Linda University Medical Center Substances et méthodes destinées à traiter les affections ou les maladies liées à l'angiopathie amyloïde cérébrale
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
JP6651506B2 (ja) * 2014-08-28 2020-02-19 タフツ・ユニバーシティ 補体関連障害を処置するための組成物、方法およびキット
BR112020016413A2 (pt) * 2018-02-12 2021-02-17 Trustees Of Tufts College cd59 de inibição de ativação do inflamassoma
JP7533896B2 (ja) * 2019-03-29 2024-08-14 公立大学法人横浜市立大学 スクリーニング方法および毒性評価法
CN113041360A (zh) * 2021-04-01 2021-06-29 深圳廷美奥生物技术有限公司 一种用于治疗年龄相关性黄斑变性的药物
AU2022394125A1 (en) 2021-11-19 2024-07-04 Janssen Biotech, Inc. Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59
WO2025074268A1 (fr) * 2023-10-02 2025-04-10 Janssen Biotech, Inc. Méthodes pour traiter la dégénérescence maculaire

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
JPS61502932A (ja) 1984-05-25 1986-12-18 デイナ−フア−バ−・キヤンサ−・インステイテユ−ト Ｌｔｒベクタ−、製法及び用途
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
US5112767A (en) 1988-03-04 1992-05-12 University Of Southern California Vectors with enhancer domains
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO1990002806A1 (fr) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Retrovirus de recombinaison a gammes d'hotes amphotropiques et ecotropiques
WO1990002797A1 (fr) 1988-09-15 1990-03-22 North Carolina State University Vecteurs retroviraux, auto-inactivants, defectifs au niveau de la replication, et cellules d'assistance pour la production de tels vecteurs
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
WO1990013641A1 (fr) 1989-05-10 1990-11-15 Sloan-Kettering Institute For Cancer Research Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii
EP0549723A1 (fr) 1990-09-21 1993-07-07 Chiron Corporation Cellules d'encapsidation
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
US5122767A (en) 1991-01-10 1992-06-16 Northern Telecom Limited Saw device tapped delay lines
ATE188740T1 (de) 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
WO1993014188A1 (fr) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible
US5627264A (en) 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1287364T3 (da) * 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
US20030086940A1 (en) 2001-08-10 2003-05-08 Cristina Costa Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
CN100594037C (zh) * 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
KR101126423B1 (ko) 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
MX2009009200A (es) 2007-03-01 2009-10-28 Advanced Vision Therapies Inc Tratamiento de enfermedades caracterizadas por la inflamacion.
US9617940B2 (en) 2014-08-14 2017-04-11 General Electric Company Engine diagnostic system and an associated method thereof

Also Published As

Publication number Publication date
ES2478820T3 (es) 2014-07-23
US20110015136A1 (en) 2011-01-20
JP2011514329A (ja) 2011-05-06
DK2252317T3 (da) 2014-07-14
WO2009102488A2 (fr) 2009-08-20
US8324182B2 (en) 2012-12-04
CA2715373A1 (fr) 2009-08-20
JP5697027B2 (ja) 2015-04-08
EP2252317A4 (fr) 2012-02-15
JP2015063534A (ja) 2015-04-09
EP2252317B1 (fr) 2014-04-09
AU2009215118B2 (en) 2015-01-22
AU2009215118A1 (en) 2009-08-20
PL2252317T3 (pl) 2014-09-30
EP2252317A2 (fr) 2010-11-24
WO2009102488A3 (fr) 2009-10-08

Similar Documents

Publication Publication Date Title
AU2009215118B2 (en) A humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US20240398898A1 (en) Compositions, kits and methods for treatment of complement-related disorders
US20230414714A1 (en) Compositions, methods and kits for treating complement related disorders
JP7656369B2 (ja) インフラマソームの活性化を阻害するためのｃｄ５９
US20140004047A1 (en) Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
US8877896B2 (en) Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
WO2012016162A2 (fr) Compositions, procédés et kits pour modéliser, diagnostiquer et traiter des troubles du complément
AU2015202046B2 (en) A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
CA2959376C (fr) Compositions, procedes et kits pour le traitement des troubles lies au complement

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140122

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250207